Hengehold Capital Management LLC Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Hengehold Capital Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 24.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 116,288 shares of the biopharmaceutical company’s stock after purchasing an additional 22,535 shares during the period. Hengehold Capital Management LLC’s holdings in Pfizer were worth $3,227,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Mather Group LLC. increased its holdings in Pfizer by 35.0% in the third quarter. Mather Group LLC. now owns 34,169 shares of the biopharmaceutical company’s stock valued at $1,133,000 after buying an additional 8,857 shares in the last quarter. Samalin Investment Counsel LLC increased its holdings in Pfizer by 8.2% in the third quarter. Samalin Investment Counsel LLC now owns 11,312 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 862 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Pfizer by 97.8% in the third quarter. Tower Research Capital LLC TRC now owns 183,802 shares of the biopharmaceutical company’s stock valued at $6,097,000 after buying an additional 90,896 shares in the last quarter. Staley Capital Advisers Inc. increased its holdings in Pfizer by 4.3% in the third quarter. Staley Capital Advisers Inc. now owns 1,346,187 shares of the biopharmaceutical company’s stock valued at $44,653,000 after buying an additional 55,290 shares in the last quarter. Finally, Bank of Nova Scotia increased its holdings in Pfizer by 219.4% in the third quarter. Bank of Nova Scotia now owns 5,503,983 shares of the biopharmaceutical company’s stock valued at $182,567,000 after buying an additional 3,780,696 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Trading Up 0.9 %

Shares of PFE traded up $0.25 during mid-day trading on Friday, reaching $28.05. The company had a trading volume of 12,418,014 shares, compared to its average volume of 40,741,414. The stock has a market cap of $158.95 billion, a price-to-earnings ratio of -467.09, a price-to-earnings-growth ratio of 1.08 and a beta of 0.70. The firm has a fifty day simple moving average of $27.81 and a 200-day simple moving average of $27.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter last year, the business earned $1.23 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.99%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.